Diabetes Type II
11
2
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Effects of Core Strengthening Exercises With Diapgragmatic Breathing Versus Core Strengthening Exercises With Pilate Breathing in Diabetes Type II Patients
Novel Biomarker for Development of T2D
Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative
Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices
The Influence of Health Beliefs and Uncertainty on Diabetes Type II Patient Compliance
A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics
A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care